Reaction

Cholestatic Liver Injury reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,115 reports · 101 co-occurring drugs

As of the last recalculation, Cholestatic Liver Injury appears in 2,115 FAERS reports alongside 101 co-occurring drug terms. The strongest observed disproportionality signal is PYRAZINAMIDE (PRR 28.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Pyrazinamide	27	28.6	28.7
Micafungin Sodium	24	28.2	28.2
Cefepime	39	27.3	27.3
Terbinafine Hydrochloride	24	26.9	27.0
Cefepime Hydrochloride	43	26.8	26.9
Temozolomide	51	24.4	24.4
Daptomycin	22	23.7	23.8
Efavirenz	26	23.2	23.3
Rifampin	30	20.5	20.5
Isoniazid	32	19.7	19.8
Amoxicillin And Clavulanate Potassium	52	19.3	19.3
Methimazole	15	18.9	19.0
Candesartan Cilexetil	48	18.4	18.4
Cefazolin Sodium	20	16.5	16.5
Dronedarone	16	15.5	15.6
Piperacillin Sodium,Tazobactam Sodium	41	15.5	15.5
Oxazepam	33	15.3	15.3
Lacosamide	52	14.1	14.1
Minocycline	16	13.6	13.6
Cefazolin	12	13.0	13.0
Enoxaparin Sodium	73	12.9	12.9
Meropenem	40	12.5	12.5
Cefuroxime	14	12.1	12.1
Ceftriaxone Sodium	44	11.5	11.5
Dalteparin Sodium	12	11.2	11.2
Itraconazole	13	11.0	11.0
Ceftriaxone	35	10.7	10.7
Cholestyramine	13	10.6	10.7
Valacyclovir	44	10.6	10.6
Captopril	10	10.3	10.3
Levetiracetam In Sodium Chloride	78	10.2	10.3
Levetiracetam Oral	78	10.2	10.3
Levetiracetam Injection	78	10.2	10.3
Lamivudine Oral	26	10.2	10.2
Piperacillin And Tazobactam	13	10.1	10.1
Doxycycline Hyclate	66	9.9	9.9
Metronidazole Topical	46	9.7	9.7
Doxycycline	65	9.6	9.6
Candesartan	34	9.5	9.5
Metronidazole	60	9.5	9.5
Ticagrelor	30	9.4	9.4
Valganciclovir Hydrochloride Powder,	11	8.9	8.9
Vismodegib	8	8.9	8.9
Febuxostat Tablets 40 Mg	9	8.7	8.7
Febuxostat Tablets 80 Mg	9	8.7	8.7
Linezolid	26	8.7	8.7
Sulfamethoxazole And Trimethoprim	71	8.5	8.5
Clindamycin	24	8.4	8.4
Lamivudine	26	8.4	8.4
Ketoprofen	11	8.3	8.3
Indapamide	15	8.3	8.3
Voriconazole Injection	18	8.2	8.2
Ciprofolxacin	57	8.0	8.0
Ciprofloxacin Tablets	57	8.0	8.0
Rifampicin	8	7.8	7.8
Clindamycin Phosphate	26	7.7	7.7
Ursosiol	15	7.6	7.6
Pravastatin Sodium	15	7.5	7.5
Moxifloxacin Hydrochloride	15	7.3	7.3
Fenofibrate	26	7.3	7.3
Vancomycin Hydrochloride	47	7.2	7.2
Valacyclovir Hydrochloride	50	7.1	7.1
Vancomycin	41	7.1	7.1
Piperacillin Sodium And Tazobactam Sodium	14	7.1	7.1
Levofloxacin	42	7.0	7.0
Levofloxacin In 5% Dextrose	42	7.0	7.0
Doxyclycline Hyclate	12	7.0	7.0
Dapagliflozin	22	6.9	6.9
Ursodiol	15	6.8	6.8
Levetiracetam	88	6.7	6.7
Vemurafenib	8	6.6	6.6
Naproxen Sodium Tablet, Coated	9	6.6	6.6
Naproxen Sodium, Coated Tablets	9	6.6	6.6
Naproxen Sodium 220Mg	9	6.6	6.6
Voriconazole	20	6.5	6.5
Azacitidine For	12	6.5	6.5
Instalax Polyethylene Glycol 3350	8	6.4	6.4
Testosterone	15	6.4	6.4
Polyethylene Glycol 400	8	6.2	6.2
Oseltamivir	5	6.2	6.2
Atovaquone	5	6.1	6.1
Dutasteride	5	6.1	6.1
Febuxostat	10	5.9	5.9
Pegaspargase	7	5.6	5.6
Insulin Degludec	13	5.5	5.5
Durvalumab	11	5.3	5.3
Trametinib	13	5.3	5.3
Amikacin	9	5.2	5.2
Dabrafenib	11	5.2	5.2
Pertuzumab	13	4.7	4.7
Norepinephrine	5	4.6	4.6
Atezolizumab	18	4.6	4.6
Testosterone Cypionate	4	4.4	4.4
Rocuronium Bromide	5	4.2	4.2
Pembrolizumab	43	4.1	4.1
Oxaliplatin	30	4.0	4.0
Azacitidine	12	4.0	4.0
Abemaciclib	8	4.0	4.0
Nivolumab	30	3.1	3.1
Ipilimumab	13	3.0	3.0
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	4	2.2	2.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.